Back to Journals » Clinical Interventions in Aging » Volume 11

Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion

Authors Michalska-Małecka K, Gaborek A, Nowak M, Halat T, Pawłowska M, Śpiewak D

Received 19 September 2015

Accepted for publication 20 January 2016

Published 23 May 2016 Volume 2016:11 Pages 699—705

DOI https://doi.org/10.2147/CIA.S96674

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Supriya Swarnkar

Peer reviewer comments 3

Editor who approved publication: Dr Richard Walker

Katarzyna Michalska-Małecka,1,2 Aneta Gaborek,2 Mariusz Nowak,3 Tomasz Halat,4 Mariola Pawłowska,2 Dorota Śpiewak2

1Department of Ophthalmology, School of Medicine in Katowice, Medical University of Silesia, Katowice, 2University Center of Ophthalmology and Oncology, Independent Public Clinical Hospital, Medical University of Silesia, Katowice, 3Pathophysiology Division, Department of Pathophysiology and Endocrinology, Medical University of Silesia, School of Medicine with Division of Density, Zabrze, 4Education and Medical Simulation Center, Medical University of Silesia, Katowice, Poland

Abstract: The purpose of this study was to evaluate the impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and functions in eyes with macular edema (ME) secondary to retinal vein occlusion. Efficacy outcomes of the treatment were best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Safety outcomes were intraocular pressure and cornea endothelial cell density. The study was conducted by the prospective analysis on 36 patients (17 women and 19 men) aged 28–77 years (the average age was 58±15 years) treated with the injection of dexamethasone implant because of the persistent ME at the Department of Ophthalmology and Ophthalmology Outpatient Clinic of the University Centre of Ophthalmology and Oncology in Katowice. The studied group included 16 patients with central retinal vein occlusion (16 eyes), and 20 patients with branch retinal vein occlusion (20 eyes). We found a significant increase of BCVA after first, second, and third month of treatment. Six months after the treatment, BCVA decreased, although not significantly compared with the value obtained in the third month. Two months after the intravitreal implantation of dexamethasone delivery system, CRT was 338±163 µm and was significantly lower compared with pretreatment value. Between third and sixth month after the treatment, we found insignificant increase of CRT compared with thickness observed in second month. Two months after the treatment, we found an increase in intraocular pressure in 36% of cases and a further decrease during the final visit 6 months after the treatment. During the treatment, there were no significant differences in endothelial cell density in branch retinal vein occlusion and central retinal vein occlusion. We found the intravitreal dexamethasone implant to be safe, well tolerated, and likely to lead to fast morphological and functional improvement of the macula and visual rehabilitation in patients with ME due to retinal vein occlusion.

Keywords: macular edema, retinal vein occlusion, intravitreal implant, dexamethasone, best-corrected visual acuity, intraocular pressure

A Letter to the Editor has been received and published for this article.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Does the use of acetylsalicylic acid have an influence on our vision?

Michalska-Małecka K, Regucka A, Śpiewak D, Sosnowska-Pońska M, Niewiem A

Clinical Interventions in Aging 2016, 11:1567-1574

Published Date: 3 November 2016

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum]

Michalska-Małecka K, Kabiesz A, Kimsa MW, Strzałka-Mrozik B, Formińska-Kapuścik M, Nita M, Mazurek U

Clinical Interventions in Aging 2016, 11:775-776

Published Date: 14 June 2016

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration

Michalska-Małecka K, Kabiesz A, Kimsa MW, Strzałka-Mrozik B, Formińska-Kapuścik M, Nita M, Mazurek U

Clinical Interventions in Aging 2016, 11:357-365

Published Date: 24 March 2016